Who Buys Cephalexin from India — 516 Importers Behind a $349.5M Market

The importation of Cephalexin from India involves various buyer segments, each with distinct purchasing behaviors:

1. Distributors: Entities like ASCEND LABORATORIES, LLC, which appears under multiple entries in our data, function as primary distributors. They procure large volumes to supply to pharmacies, hospitals, and healthcare providers. Their purchasing patterns are characterized by bulk orders and a high frequency of transactions to maintain a steady supply chain.

2. Hospital Groups: Organizations such as M/S. SUN PHARMA ANZ PTY LTD in Australia likely represent hospital groups or healthcare networks. They import Cephalexin to meet the therapeutic needs of their patient populations, often engaging in tender-based procurement to secure favorable pricing and ensure consistent supply.

3. Retail Chains: While not explicitly listed among the top buyers, retail pharmacy chains in various countries import Cephalexin to stock their outlets. Their purchasing behavior includes regular, moderate-sized orders to align with consumer demand and manage inventory effectively.

4. Government Procurement: Entities like BREATHEFREE LANKA PVT LTD in Sri Lanka may be involved in government procurement processes, supplying Cephalexin for public health initiatives. These buyers typically engage in large-scale, periodic purchases through formal tender processes to ensure the availability of essential medicines in public healthcare facilities.

5. Re-exporters: Companies such as UNIQUE PHARMA in the Democratic Republic of Congo might act as re-exporters, importing Cephalexin from India to distribute it to neighboring regions. Their purchasing patterns involve bulk acquisitions, followed by redistribution to various markets.

6. Contract Manufacturers: Some buyers may function as contract manufacturers, importing Cephalexin as an active pharmaceutical ingredient (API) for formulation into finished products. Their procurement is characterized by large, consistent orders aligned with production schedules.

United States

1. Drug Regulatory Authority: U.S. Food and Drug Administration (FDA).

2. Import Registration Process for Cephalexin: Importers must ensure that Cephalexin is manufactured in facilities compliant with FDA regulations. The product must be approved under an Abbreviated New Drug Application (ANDA) or a New Drug Application (NDA).

3. Estimated Timeline for Registration: The approval process for an ANDA typically takes 10 months, though timelines can vary based on the completeness of the application and FDA workload.

4. Import Tariff/Duty for HS 30042012: Pharmaceutical products under HS Code 30042012 are generally duty-free in the United States.

Sri Lanka

1. Drug Regulatory Authority: National Medicines Regulatory Authority (NMRA).

2. Import Registration Process for Cephalexin: Importers must obtain registration from the NMRA, which involves submitting product dossiers, certificates of analysis, and compliance with labeling requirements.

3. Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the completeness of the submission and regulatory reviews.

4. Import Tariff/Duty for HS 30042012: Pharmaceuticals under this HS code are subject to a duty of 0% to 15%, depending on the product and applicable trade agreements.

Australia

1. Drug Regulatory Authority: Therapeutic Goods Administration (TGA).

2. Import Registration Process for Cephalexin: Cephalexin must be listed or registered in the Australian Register of Therapeutic Goods (ARTG). Importers need to provide evidence of Good Manufacturing Practice (GMP) compliance and product efficacy.

3. Estimated Timeline for Registration: The registration process can take 6 to 12 months, depending on the category of registration and the quality of the application.

4. Import Tariff/Duty for HS 30042012: Pharmaceutical products under this HS code are generally duty-free in Australia.

Ecuador

1. Drug Regulatory Authority: Agencia Nacional de Regulación, Control y Vigilancia Sanitaria (ARCSA).

2. Import Registration Process for Cephalexin: Importers must register the product with ARCSA, providing documentation on product quality, safety, and efficacy.

3. Estimated Timeline for Registration: The registration process typically takes 6 to 9 months, subject to the completeness of the application and regulatory assessments.

4. Import Tariff/Duty for HS 30042012: Pharmaceuticals under this HS code are subject to a duty of approximately 5%, though rates can vary based on trade agreements.

Tanzania

1. Drug Regulatory Authority: Tanzania Medicines and Medical Devices Authority (TMDA).

2. Import Registration Process for Cephalexin: Importers must register Cephalexin with the TMDA, submitting product dossiers, GMP certificates, and samples for evaluation.

3. Estimated Timeline for Registration: The registration process can take 12 to 18 months, depending on the thoroughness of the submission and regulatory review processes.

4. Import Tariff/Duty for HS 30042012: Pharmaceutical products under this HS code are generally exempt from import duties in Tanzania.

The demand for Cephalexin in importing countries is influenced by several factors:

1. Disease Prevalence: Cephalexin is commonly prescribed for bacterial infections such as respiratory tract infections, skin infections, and urinary tract infections. High prevalence rates of these conditions in various regions drive the demand for effective antibiotics.

2. Government Healthcare Programs: Many countries have implemented healthcare programs aimed at improving access to essential medicines. For instance, the WHO recommends tendering for pharmaceutical products, considering factors like product quality, availability, and supply security.

3. Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased procurement of essential medicines, including antibiotics like Cephalexin, to ensure broader access to healthcare services.

4. WHO Essential Medicines List Procurement: Cephalexin's inclusion in the WHO Essential Medicines List prompts countries to prioritize its procurement to meet public health needs.

5. Tender-Based Purchasing: Many governments and healthcare organizations utilize tender-based purchasing to procure medicines cost-effectively. This approach ensures a steady supply of essential drugs like Cephalexin, aligning with public health objectives.

Our data indicates that 516 buyers across 104 countries have imported Cephalexin from India, reflecting its global demand and the critical role it plays in treating bacterial infections worldwide.

The importation of Cephalexin from India involves various buyer segments, each with distinct purchasing behaviors:

1. Distributors: Entities like ASCEND LABORATORIES, LLC, which appears under multiple entries in our data, function as primary distributors. They procure large volumes to supply to pharmacies, hospitals, and healthcare providers. Their purchasing patterns are characterized by bulk orders and a high frequency of transactions to maintain a steady supply chain.

2. Hospital Groups: Organizations such as M/S. SUN PHARMA ANZ PTY LTD in Australia likely represent hospital groups or healthcare networks. They import Cephalexin to meet the therapeutic needs of their patient populations, often engaging in tender-based procurement to secure favorable pricing and ensure consistent supply.

3. Retail Chains: While not explicitly listed among the top buyers, retail pharmacy chains in various countries import Cephalexin to stock their outlets. Their purchasing behavior includes regular, moderate-sized orders to align with consumer demand and manage inventory effectively.

4. Government Procurement: Entities like BREATHEFREE LANKA PVT LTD in Sri Lanka may be involved in government procurement processes, supplying Cephalexin for public health initiatives. These buyers typically engage in large-scale, periodic purchases through formal tender processes to ensure the availability of essential medicines in public healthcare facilities.

5. Re-exporters: Companies such as UNIQUE PHARMA in the Democratic Republic of Congo might act as re-exporters, importing Cephalexin from India to distribute it to neighboring regions. Their purchasing patterns involve bulk acquisitions, followed by redistribution to various markets.

6. Contract Manufacturers: Some buyers may function as contract manufacturers, importing Cephalexin as an active pharmaceutical ingredient (API) for formulation into finished products. Their procurement is characterized by large, consistent orders aligned with production schedules.

United States

1. Drug Regulatory Authority: U.S. Food and Drug Administration (FDA).

2. Import Registration Process for Cephalexin: Importers must ensure that Cephalexin is manufactured in facilities compliant with FDA regulations. The product must be approved under an Abbreviated New Drug Application (ANDA) or a New Drug Application (NDA).

3. Estimated Timeline for Registration: The approval process for an ANDA typically takes 10 months, though timelines can vary based on the completeness of the application and FDA workload.

4. Import Tariff/Duty for HS 30042012: Pharmaceutical products under HS Code 30042012 are generally duty-free in the United States.

Sri Lanka

1. Drug Regulatory Authority: National Medicines Regulatory Authority (NMRA).

2. Import Registration Process for Cephalexin: Importers must obtain registration from the NMRA, which involves submitting product dossiers, certificates of analysis, and compliance with labeling requirements.

3. Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the completeness of the submission and regulatory reviews.

4. Import Tariff/Duty for HS 30042012: Pharmaceuticals under this HS code are subject to a duty of 0% to 15%, depending on the product and applicable trade agreements.

Australia

1. Drug Regulatory Authority: Therapeutic Goods Administration (TGA).

2. Import Registration Process for Cephalexin: Cephalexin must be listed or registered in the Australian Register of Therapeutic Goods (ARTG). Importers need to provide evidence of Good Manufacturing Practice (GMP) compliance and product efficacy.

3. Estimated Timeline for Registration: The registration process can take 6 to 12 months, depending on the category of registration and the quality of the application.

4. Import Tariff/Duty for HS 30042012: Pharmaceutical products under this HS code are generally duty-free in Australia.

Ecuador

1. Drug Regulatory Authority: Agencia Nacional de Regulación, Control y Vigilancia Sanitaria (ARCSA).

2. Import Registration Process for Cephalexin: Importers must register the product with ARCSA, providing documentation on product quality, safety, and efficacy.

3. Estimated Timeline for Registration: The registration process typically takes 6 to 9 months, subject to the completeness of the application and regulatory assessments.

4. Import Tariff/Duty for HS 30042012: Pharmaceuticals under this HS code are subject to a duty of approximately 5%, though rates can vary based on trade agreements.

Tanzania

1. Drug Regulatory Authority: Tanzania Medicines and Medical Devices Authority (TMDA).

2. Import Registration Process for Cephalexin: Importers must register Cephalexin with the TMDA, submitting product dossiers, GMP certificates, and samples for evaluation.

3. Estimated Timeline for Registration: The registration process can take 12 to 18 months, depending on the thoroughness of the submission and regulatory review processes.

4. Import Tariff/Duty for HS 30042012: Pharmaceutical products under this HS code are generally exempt from import duties in Tanzania.

The demand for Cephalexin in importing countries is influenced by several factors:

1. Disease Prevalence: Cephalexin is commonly prescribed for bacterial infections such as respiratory tract infections, skin infections, and urinary tract infections. High prevalence rates of these conditions in various regions drive the demand for effective antibiotics.

2. Government Healthcare Programs: Many countries have implemented healthcare programs aimed at improving access to essential medicines. For instance, the WHO recommends tendering for pharmaceutical products, considering factors like product quality, availability, and supply security.

3. Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased procurement of essential medicines, including antibiotics like Cephalexin, to ensure broader access to healthcare services.

4. WHO Essential Medicines List Procurement: Cephalexin's inclusion in the WHO Essential Medicines List prompts countries to prioritize its procurement to meet public health needs.

5. Tender-Based Purchasing: Many governments and healthcare organizations utilize tender-based purchasing to procure medicines cost-effectively. This approach ensures a steady supply of essential drugs like Cephalexin, aligning with public health objectives.

Our data indicates that 516 buyers across 104 countries have imported Cephalexin from India, reflecting its global demand and the critical role it plays in treating bacterial infections worldwide.